MediLink Therapeutics has appointed China International Capital Corp, JPMorgan Chase, and Morgan Stanley for a planned IPO in Hong Kong, Bloomberg News reported Wednesday, citing people familiar with the matter.
The Suzhou, China-based biotechnology firm is targeting a raise of over $100 million, though discussions are still ongoing and terms may change, the report said.
MediLink, JPMorgan, and Morgan Stanley declined to comment, while CICC did not respond, Bloomberg said.
Founded in 2020, MediLink is a clinical-stage biotech company that focuses on antibody drugs, with research and development sites in Shanghai and Boston, the report added.
(Market Chatter news is derived from conversations with market professionals globally. This information is believed to be from reliable sources but may include rumor and speculation. Accuracy is not guaranteed.)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.